| Year |
Citation |
Score |
| 2020 |
Schmidt CR, Achille NJ, Kuntimaddi A, Boulton AM, Leach BI, Zhang S, Zeleznik-Le NJ, Bushweller JH. BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity. Blood Cancer Discovery. 1: 162-177. PMID 32954361 DOI: 10.1158/2643-3230.BCD-20-0036 |
0.423 |
|
| 2018 |
Bushweller JH, Schmidt C, Achille N, Kuntimaddi A, Boulton A, Leach B, Zhang S, Zeleznik-Le NJ. Direct Binding of BCOR, but Not CBX8, to MLL-AF9 Is Essential for MLL-AF9 Leukemia Via Regulation of the EYA1/SIX1 Gene Network Blood. 132: 1316-1316. DOI: 10.1182/Blood-2018-99-111388 |
0.568 |
|
| 2016 |
Zeleznik-Le NJ. One Step Forward in the Challenging Arena of MLL-AF4 Leukemia. Cancer Cell. 30: 657-658. PMID 27846384 DOI: 10.1016/J.Ccell.2016.10.017 |
0.308 |
|
| 2016 |
Mian YA, Zeleznik-Le NJ. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1. Leukemia Research. 46: 51-60. PMID 27123834 DOI: 10.1016/J.Leukres.2016.04.006 |
0.315 |
|
| 2016 |
Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S, Zeleznik-Le NJ. Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leukemia Research. PMID 26818573 DOI: 10.1016/J.Leukres.2016.01.004 |
0.406 |
|
| 2015 |
Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Reports. 11: 808-20. PMID 25921540 DOI: 10.1016/J.Celrep.2015.04.004 |
0.803 |
|
| 2015 |
Bushweller J, Kuntimaddi A, Thorpe J, Achille N, Lokken A, Singh R, Adli M, Zeleznik-Le N. Intrinsic Disorder, Epigenetics, and Leukemia - the MLL-AF9 SAGA Biophysical Journal. 108: 5a. DOI: 10.1016/J.Bpj.2014.11.045 |
0.808 |
|
| 2014 |
Lokken AA, Achille NJ, Chang MJ, Lin JJ, Kuntimaddi A, Leach BI, Malik B, Nesbit JB, Zhang S, Bushweller JH, Zeleznik-Le NJ, Hemenway CS. Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4. Leukemia Research. 38: 1309-15. PMID 25282333 DOI: 10.1016/J.Leukres.2014.08.010 |
0.777 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of Clinical Investigation. 124: 222-36. PMID 24334453 DOI: 10.1172/Jci66005 |
0.441 |
|
| 2014 |
Mian YA, Zeleznik-Le NJ. The Mir-17-92 Cluster Contributes to MLL Leukemia through the Repression of PKNOX1, a MEIS1 Competitor Blood. 124: 877-877. DOI: 10.1182/Blood.V124.21.877.877 |
0.38 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Meyer S, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, et al. Abstract 979: microRNA-mediated leukemia-initiating cell activity Cancer Research. 74: 979-979. DOI: 10.1158/1538-7445.Am2014-979 |
0.388 |
|
| 2013 |
Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, Zeleznik-Le NJ. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. The Journal of Biological Chemistry. 288: 29901-10. PMID 23990460 DOI: 10.1074/Jbc.M113.474858 |
0.767 |
|
| 2013 |
Zhang J, Seet CS, Sun C, Li J, You D, Volk A, Breslin P, Li X, Wei W, Qian Z, Zeleznik-Le NJ, Zhang Z, Zhang J. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Molecular Oncology. 7: 1069-82. PMID 23988911 DOI: 10.1016/J.Molonc.2013.07.011 |
0.348 |
|
| 2013 |
Kuntimaddi A, Lokken A, Zhang S, Thorpe J, Leach B, Lumba B, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH. Structural and Functional Studies Of The Intrinsically Disordered Protein AF9 In MLL-AF9 Leukemia Blood. 122: 3762-3762. DOI: 10.1182/Blood.V122.21.3762.3762 |
0.802 |
|
| 2012 |
Lokken AA, Zeleznik-Le NJ. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell. 21: 451-3. PMID 22516254 DOI: 10.1016/J.Ccr.2012.03.027 |
0.757 |
|
| 2012 |
Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, ... ... Zeleznik-Le NJ, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature Communications. 3: 688. PMID 22353710 DOI: 10.1038/Ncomms1681 |
0.302 |
|
| 2011 |
Achille N, Michaelis L, Smith SE, Germano E, Zeleznik-Le NJ, Nand S. Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs) Blood. 118: 4625-4625. DOI: 10.1182/Blood.V118.21.4625.4625 |
0.401 |
|
| 2011 |
Bushweller JH, Leach B, Chang M, Lumba B, Cierpicki T, Zeleznik-Le NJ, Hemenway CS. The Role of the Intrinsically Disordered and Multifunctional AF9 C-Terminal Domain in MLL-AF9 Leukemia, Blood. 118: 3464-3464. DOI: 10.1182/Blood.V118.21.3464.3464 |
0.526 |
|
| 2011 |
Birch N, Zeleznik-Le N. Abstract 4014: Determination of critical residues within the CXXC domain of MLL fusions which contribute to leukemic transformation Cancer Research. 71: 4014-4014. DOI: 10.1158/1538-7445.Am2011-4014 |
0.554 |
|
| 2010 |
Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, Zeleznik-Le NJ, Hemenway CS, Zhang W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Research. 70: 10234-42. PMID 21159644 DOI: 10.1158/0008-5472.Can-10-3294 |
0.412 |
|
| 2010 |
Birch NW, Zeleznik-Le NJ. Glycogen synthase kinase-3 and leukemia: restoring the balance. Cancer Cell. 17: 529-31. PMID 20541696 DOI: 10.1016/J.Ccr.2010.05.017 |
0.303 |
|
| 2010 |
Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H, Luo RT, Sun M, He M, Neilly MB, Zeleznik-Le NJ, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proceedings of the National Academy of Sciences of the United States of America. 107: 3710-5. PMID 20133587 DOI: 10.1073/Pnas.0914900107 |
0.309 |
|
| 2010 |
Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nature Structural & Molecular Biology. 17: 62-8. PMID 20010842 DOI: 10.1038/Nsmb.1714 |
0.805 |
|
| 2010 |
Risner LE, Kuntimaddi A, Bushweller JH, Zeleznik-Le NJ. DNMT1 Cxxc Domain Can Functionally Substitute In An MLL Fusion Protein Blood. 116: 4193-4193. DOI: 10.1182/Blood.V116.21.4193.4193 |
0.82 |
|
| 2010 |
Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Zeleznik-Le N, Jordan CT, Carroll M, Gebelein B, Grimes HL. Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance Blood. 116: 4192-4192. DOI: 10.1182/Blood.V116.21.4192.4192 |
0.454 |
|
| 2009 |
Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, Chen J, Rowley JD, Zeleznik-Le NJ. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 113: 3314-22. PMID 19188669 DOI: 10.1182/Blood-2008-04-154310 |
0.655 |
|
| 2009 |
Risner L, Cierpicki T, Grembecka J, Lukasik SM, Popovic R, Shultis DS, Zeleznik-Le NJ, Bushweller JH. Structural Basis for MLL Cxxc Domain Protection against CpG DNA Methylation and the Essential Role of This Function in MLL-AF9 Leukemia. Blood. 114: 763-763. DOI: 10.1182/Blood.V114.22.763.763 |
0.797 |
|
| 2009 |
Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Risner L, Zeleznik-Le NJ, Jordan CT, Carroll M, Gebelein B, Grimes HL. Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation. Blood. 114: 3966-3966. DOI: 10.1182/Blood.V114.22.3966.3966 |
0.8 |
|
| 2008 |
Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman MJ, Zeleznik-Le NJ, Diaz MO. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Research. 68: 6199-207. PMID 18676843 DOI: 10.1158/0008-5472.Can-07-6514 |
0.706 |
|
| 2008 |
Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia ZB, Stuart T, Diaz MO, Bushweller JH, Zeleznik-Le NJ. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proceedings of the National Academy of Sciences of the United States of America. 105: 7517-22. PMID 18483194 DOI: 10.1073/Pnas.0800090105 |
0.737 |
|
| 2008 |
Popovic R, Erfurth F, Zeleznik-Le N. Transcriptional complexity of the HOXA9 locus. Blood Cells, Molecules & Diseases. 40: 156-9. PMID 17916434 DOI: 10.1016/J.Bcmd.2007.07.016 |
0.686 |
|
| 2007 |
Baron BW, Zeleznik-Le N, Baron MJ, Theisler C, Huo D, Krasowski MD, Thirman MJ, Baron RM, Baron JM. Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 104: 7449-54. PMID 17468402 DOI: 10.1073/Pnas.0701770104 |
0.39 |
|
| 2006 |
Santillan DA, Theisler CM, Ryan AS, Popovic R, Stuart T, Zhou MM, Alkan S, Zeleznik-Le NJ. Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype. Cancer Research. 66: 10032-9. PMID 17047066 DOI: 10.1158/0008-5472.Can-06-2597 |
0.792 |
|
| 2005 |
Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, Zeleznik-Le NJ. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proceedings of the National Academy of Sciences of the United States of America. 102: 14028-33. PMID 16169901 DOI: 10.1073/Pnas.0506464102 |
0.791 |
|
| 2005 |
Popovic R, Zeleznik-Le NJ. MLL: how complex does it get? Journal of Cellular Biochemistry. 95: 234-42. PMID 15779005 DOI: 10.1002/Jcb.20430 |
0.713 |
|
| 2005 |
Zeleznik-Le NJ. Leukemia RNAi: Harnessing the killer within Blood. 106: 3336-3337. DOI: 10.1182/Blood-2005-08-3500 |
0.379 |
|
| 2004 |
Zhang Y, Zeleznik-Le N, Emmanuel N, Jayathilaka N, Chen J, Strissel P, Strick R, Li L, Neilly MB, Taki T, Hayashi Y, Kaneko Y, Schlegelberger B, Rowley JD. Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16). Genes, Chromosomes & Cancer. 41: 257-65. PMID 15334549 DOI: 10.1002/Gcc.20077 |
0.325 |
|
| 2004 |
Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, Sanchez R, Zeleznik-Le NJ, Ronai Z, Zhou MM. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Molecular Cell. 13: 251-63. PMID 14759370 DOI: 10.1016/S1097-2765(03)00528-8 |
0.432 |
|
| 2004 |
Xia Z, Popovic R, Lorenz T, Santillan D, Erfurth F, Zeleznik-Le NJ. MLL-AF4 Down-Regulates CDKN1B (P27) Independent of Cell Cycle Progression. Blood. 104: 2563-2563. DOI: 10.1182/Blood.V104.11.2563.2563 |
0.782 |
|
| 2004 |
Santillan DA, Ryan AS, Zeleznik-Le NJ. MLL Partner Gene Domains Contribute Critical Functional Specificity to Immortalization and Differentiation of Hematopoietic Progenitors. Blood. 104: 2555-2555. DOI: 10.1182/Blood.V104.11.2555.2555 |
0.683 |
|
| 2003 |
Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proceedings of the National Academy of Sciences of the United States of America. 100: 8342-7. PMID 12829790 DOI: 10.1073/Pnas.1436338100 |
0.543 |
|
| 2003 |
Echlin-Bell DR, Smith LL, Li L, Strissel PL, Strick R, Gupta V, Banerjee J, Larson R, Relling MV, Raimondi SC, Hayashi Y, Taki T, Zeleznik-Le N, Rowley JD. Polymorphisms in the MLL breakpoint cluster region (BCR). Human Genetics. 113: 80-91. PMID 12665971 DOI: 10.1007/S00439-003-0936-2 |
0.309 |
|
| 2003 |
Kuefer MU, Chinwalla V, Zeleznik-Le NJ, Behm FG, Naeve CW, Rakestraw KM, Mukatira ST, Raimondi SC, Morris SW. Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14). Oncogene. 22: 1418-24. PMID 12618768 DOI: 10.1038/Sj.Onc.1206272 |
0.408 |
|
| 2003 |
Chinwalla V, Chien A, Odero M, Neilly MB, Zeleznik-Le NJ, Rowley JD. A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15. Oncogene. 22: 1400-10. PMID 12618766 DOI: 10.1038/Sj.Onc.1206273 |
0.459 |
|
| 2002 |
Macara IG, Baldarelli R, Field CM, Glotzer M, Hayashi Y, Hsu SC, Kennedy MB, Kinoshita M, Longtine M, Low C, Maltais LJ, McKenzie L, Mitchison TJ, Nishikawa T, Noda M, ... ... Zeleznik-Le NJ, et al. Mammalian septins nomenclature. Molecular Biology of the Cell. 13: 4111-3. PMID 12475938 DOI: 10.1091/Mbc.E02-07-0438 |
0.323 |
|
| 2002 |
Odero MD, Vizmanos JL, Román JP, Lahortiga I, Panizo C, Calasanz MJ, Zeleznik-Le NJ, Rowley JD, Novo FJ. A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes, Chromosomes & Cancer. 35: 11-9. PMID 12203785 DOI: 10.1002/Gcc.10090 |
0.407 |
|
| 2002 |
Baron BW, Anastasi J, Thirman MJ, Furukawa Y, Fears S, Kim DC, Simone F, Birkenbach M, Montag A, Sadhu A, Zeleznik-Le N, McKeithan TW. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis Proceedings of the National Academy of Sciences of the United States of America. 99: 2860-2865. PMID 11854457 DOI: 10.1073/Pnas.042702599 |
0.43 |
|
| 2001 |
Liedman D, Zeleznik-Le N. Retroviral transduction model of mixed lineage leukemia fused to CREB binding protein. Current Opinion in Hematology. 8: 218-23. PMID 11561159 DOI: 10.1097/00062752-200107000-00007 |
0.445 |
|
| 2001 |
Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-Le NJ, Mrózek K, Theil KS, Kees UR, Bloomfield CD, Caligiuri MA. The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. Cancer Research. 61: 59-63. PMID 11196198 |
0.318 |
|
| 2000 |
Odero MD, Zeleznik-Le NJ, Chinwalla V, Rowley JD. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation Genes Chromosomes and Cancer. 29: 333-338. PMID 11066077 DOI: 10.1002/1098-2264(2000)9999:9999<::Aid-Gcc1040>3.0.Co;2-Z |
0.379 |
|
| 2000 |
Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. The Embo Journal. 19: 4655-64. PMID 10970858 DOI: 10.1093/emboj/19.17.4655 |
0.46 |
|
| 2000 |
Strissel PL, Strick R, Tomek RJ, Roe BA, Rowley JD, Zeleznik-Le NJ. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis Human Molecular Genetics. 9: 1671-1679. PMID 10861294 DOI: 10.1093/Hmg/9.11.1671 |
0.452 |
|
| 1999 |
Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25) Proceedings of the National Academy of Sciences of the United States of America. 96: 6428-6433. PMID 10339604 DOI: 10.1073/Pnas.96.11.6428 |
0.429 |
|
| 1998 |
Atlas M, Head D, Behm F, Schmidt E, Zeleznik-Le NJ, Roe BA, Burian D, Domer PH. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints Leukemia. 12: 1895-1902. PMID 9844920 DOI: 10.1038/Sj.Leu.2401223 |
0.381 |
|
| 1998 |
Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region Blood. 92: 3793-3803. PMID 9808573 DOI: 10.1182/Blood.V92.10.3793.422A24_3793_3803 |
0.368 |
|
| 1998 |
Allen RJ, Smith SD, Moldwin RL, Lu MM, Giordano L, Vignon C, Suto Y, Harden A, Tomek R, Veldman T, Ried T, Larson RA, Le Beau MM, Rowley JD, Zeleznik-Le N. Establishment and characterization of a megakaryoblast cell line with amplification of MLL. Leukemia. 12: 1119-27. PMID 9665199 DOI: 10.1038/Sj.Leu.2401002 |
0.323 |
|
| 1997 |
Super HG, Strissel PL, Sobulo OM, Burian D, Reshmi SC, Roe B, Zeleznik-Le NJ, Diaz MO, Rowley JD. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia Genes Chromosomes and Cancer. 20: 185-195. PMID 9331569 DOI: 10.1002/(Sici)1098-2264(199710)20:2<185::Aid-Gcc9>3.0.Co;2-# |
0.418 |
|
| 1997 |
Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proceedings of the National Academy of Sciences of the United States of America. 94: 8732-7. PMID 9238046 DOI: 10.1073/Pnas.94.16.8732 |
0.573 |
|
| 1997 |
Baron BW, Desai M, Baber LJ, Paras L, Zhang Q, Sadhu A, Duguay S, Nucifora G, McKeithan TW, Zeleznik-Le N. BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region. Genes, Chromosomes & Cancer. 19: 14-21. PMID 9135990 DOI: 10.1002/(Sici)1098-2264(199705)19:1<14::Aid-Gcc3>3.0.Co;2-3 |
0.404 |
|
| 1997 |
Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N. All Patients With the T(11; 16)(q23; p13.3) That Involves MLL and CBP Have Treatment-Related Hematologic Disorders Blood. 90: 535-541. DOI: 10.1182/Blood.V90.2.535.535_535_541 |
0.448 |
|
| 1996 |
Tanabe S, Bohlander SK, Vignon CV, Espinosa R, Zhao N, Strissel PL, Zeleznik-Le NJ, Rowley JD. AF10 is split by MLL and HEAB, a human homolog to a putative Caenorhabditis elegans ATP/GTP-binding protein in an invins(10;11)(p12;q23q12) Blood. 88: 3535-3545. PMID 8896421 DOI: 10.1182/Blood.V88.9.3535.Bloodjournal8893535 |
0.487 |
|
| 1996 |
Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R, LeBeau MM, Thirman MJ, Rowley JD. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line Genes Chromosomes and Cancer. 15: 206-216. PMID 8703846 DOI: 10.1002/(Sici)1098-2264(199604)15:4<206::Aid-Gcc2>3.0.Co;2-5 |
0.381 |
|
| 1996 |
Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proceedings of the National Academy of Sciences of the United States of America. 93: 1642-7. PMID 8643684 DOI: 10.1073/Pnas.93.4.1642 |
0.435 |
|
| 1996 |
Broeker PL, Harden A, Rowley JD, Zeleznik-Le N. The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA. Current Topics in Microbiology and Immunology. 211: 259-68. PMID 8585957 DOI: 10.1007/978-3-642-85232-9_26 |
0.592 |
|
| 1995 |
Baron BW, Stanger RR, Hume E, Sadhu A, Mick R, Kerckaert JP, Deweindt C, Bastard C, Nucifora G, Zeleznik-Le N. BCL6 encodes a sequence-specific DNA-binding protein. Genes, Chromosomes & Cancer. 13: 221-4. PMID 7669744 DOI: 10.1002/Gcc.2870130314 |
0.447 |
|
| 1994 |
Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proceedings of the National Academy of Sciences of the United States of America. 91: 10610-4. PMID 7938000 DOI: 10.1073/Pnas.91.22.10610 |
0.583 |
|
| 1992 |
Zeleznik-Le NJ, Itoh-Lindstrom Y, Clarke JB, Moore TL, Ting JP. The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA. The Journal of Biological Chemistry. 267: 7677-82. PMID 1560002 |
0.362 |
|
| 1990 |
Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, Ting JP, Glimcher LH. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science (New York, N.Y.). 247: 1581-4. PMID 2321018 DOI: 10.1126/Science.2321018 |
0.34 |
|
| Show low-probability matches. |